Different studies have reported on the importance of IL-4 and GMCSF in glioma development and/or progression (55–57), showing an enhanced risk and worse outcome of GBM for people that carry certain polymorphisms in IL-4R and STAT-6 gene loci (12–15). This evidence concerns the gene IL4 and central nervous system cancer.